Clara D Bloomfield

The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP.

R. Gascoyne, L. Sehn, J. Connors, 2007, Blood.

Clinical Trials and Observations

C. Bloomfield, L. Staudt, A. Rosenwald, 2005 .

children with AML in remission : Pediatric Oncology Group Study 9421 Randomized use of cyclosporin A ( CsA ) to modulate P-glycoprotein in

F. Behm, S. Raimondi, M. Qumsiyeh, 2005 .

Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: Results of a pros

W. Hiddemann, M. Qumsiyeh, H. Einsele, 2006, Blood.

NCCN Clinical Practice Guidelines in Oncology: myelodysplastic syndromes.

M. Millenson, P. Westervelt, G. Garcia-Manero, 2011, Journal of the National Comprehensive Cancer Network : JNCCN.